Home
About
Overview
Sharing Data
ORCID
Help
History (6)
Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis.
Extracranial Etiology of Acute Onset Ataxia and Weakness: Small but Deadly.
Higher blood glucose is associated with the severity of hemorrhagic transformation after endovascular therapy for stroke.
Quantifying Cancer: More Than Just a Numbers Game.
MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer.
See All 6 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer.
MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer. J Thorac Oncol. 2016 09; 11(9):1381-3.
View in:
PubMed
subject areas
Exons
Humans
Lung Neoplasms
Mutation
authors with profiles
Ravi Salgia